Avecho licenses TPM® for development of enhanced cancer drugs
Avecho has today announced it has entered into a strategic partnership with Arthur Group for the development of enhanced cancer drugs using TPM®.
Founded in December 2015, Arthur Pharma focuses on the research and development, manufacturing, and marketing of complex generic, 505B2, and NCE pharmaceutical products – and currently develops and manufactures 23 commercial oncology products. It is focused on the North American, European, and Asian markets.
Under the terms of the agreement, Arthur Group will pay for all formulation, non-clinical and clinical development of the products – and Avecho will receive 30% of revenue from licensing and 30% of net profit from commercialisation of these products.
Arthur Group CEO, Dr Isaac Liu, commented:
“We are very interested to begin formulation work with TPM. Should it prove possible to replace cremaphor or other adverse excipients in existing oncology therapies with a form of vitamin E that is safe for injection, we would anticipate the product to have significant global interest. We are interested in extending the cooperation into a portfolio of cancer drugs.”